| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/01/2001 | WO2000009668A9 Engraftable human neural stem cells |
| 02/01/2001 | WO1999066951A8 Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| 02/01/2001 | WO1999041376A9 Retinoblastoma protein complexes and retinoblastoma interacting proteins |
| 02/01/2001 | WO1997045137A8 Methods and compositions useful for inhibition of angiogenesis |
| 02/01/2001 | DE19935219A1 Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung Carboxamides, medicaments containing these compounds, their use and production |
| 02/01/2001 | DE19934432A1 Indolderivate Indole derivatives |
| 02/01/2001 | CA2718926A1 Methods of reducing microbial resistance to drugs |
| 02/01/2001 | CA2696819A1 Ghrelin related peptides |
| 02/01/2001 | CA2689694A1 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 02/01/2001 | CA2383017A1 Imidazoimidazoles and triazoles as anti-inflammatory agents |
| 02/01/2001 | CA2382757A1 Carboxylic acid derivatives and adhesion molecule inhibitors which contain the same as effective ingredients |
| 02/01/2001 | CA2382755A1 Substituted oxoazaheterocyclyl compounds |
| 02/01/2001 | CA2380389A1 Biarylurea derivatives |
| 02/01/2001 | CA2380317A1 Human synthetases |
| 02/01/2001 | CA2380226A1 Novel fibroblast growth factor and nucleic acids encoding same |
| 02/01/2001 | CA2380218A1 Novel thiazine or pyrazine derivatives |
| 02/01/2001 | CA2380206A1 Pharmaceutical compositions exhibiting thrombopoietin receptor agonism |
| 02/01/2001 | CA2380192A1 Oligonucleotides for inhibiting the expression of human eg5 |
| 02/01/2001 | CA2380037A1 Vgf polypeptides and methods of treating vgf-related disorders |
| 02/01/2001 | CA2379834A1 Enzyme catalyzed anti-infective therapeutic agents |
| 02/01/2001 | CA2379802A1 Drosophila recombination-associated protein and methods for use |
| 02/01/2001 | CA2379801A1 Receptors and associated proteins |
| 02/01/2001 | CA2379784A1 Cell cycle and proliferation proteins |
| 02/01/2001 | CA2379777A1 Isolated peptide of the horny layer and use thereof |
| 02/01/2001 | CA2379659A1 Antisense modulation of pten expression |
| 02/01/2001 | CA2379398A1 Nociceptin receptor orl-1 agonists for use in treating cough |
| 02/01/2001 | CA2379237A1 Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases |
| 02/01/2001 | CA2378860A1 Bicyclic antagonists selective for the .alpha.v.beta.3 integrin |
| 02/01/2001 | CA2378849A1 Apicidin-derived cyclic tetrapeptides |
| 02/01/2001 | CA2378845A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 02/01/2001 | CA2378643A1 Muscle cells and their use in cardiac repair |
| 02/01/2001 | CA2378462A1 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | CA2378403A1 Novel polynucleotides and method for the use thereof |
| 01/31/2001 | EP1072680A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/31/2001 | EP1072609A2 Cytoprotective agents comprising prosaposin-related peptides |
| 01/31/2001 | EP1072601A2 4-arylpiperidine derivatives for the treatment of pruritus |
| 01/31/2001 | EP1072266A1 Thienylazolylalcoxyethanamines, their preparation and their application as medicaments |
| 01/31/2001 | EP1072254A1 Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis |
| 01/31/2001 | EP1071959A2 Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway |
| 01/31/2001 | EP1071955A1 Improved immunodiagnostic assays using reducing agents |
| 01/31/2001 | EP1071792A2 Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins |
| 01/31/2001 | EP1071787A1 Tao protein kinases and methods of use |
| 01/31/2001 | EP1071781A1 B-cell growth factor related protein |
| 01/31/2001 | EP1071780A1 Soluble protein ztmpo-1 |
| 01/31/2001 | EP1071772A2 Fizz proteins |
| 01/31/2001 | EP1071745A2 Process for synthesizing cox-2 inhibitors |
| 01/31/2001 | EP1071718A1 Matrix binding factor |
| 01/31/2001 | EP1071708A1 Edg family gene, human h218 |
| 01/31/2001 | EP1071707A1 Novel omega conotoxin peptides |
| 01/31/2001 | EP1071704A1 Novel matrix metalloproteinase inhibitors and down-regulators |
| 01/31/2001 | EP1071702A1 Fatty acid derivatives of bile acids and bile acid derivatives |
| 01/31/2001 | EP1071701A1 Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| 01/31/2001 | EP1071699A1 Enhanced antisense modulation of icam-1 |
| 01/31/2001 | EP1071698A1 Nucleic acid sequences and proteins associated with aging |
| 01/31/2001 | EP1071697A1 Regulated target expression for screening |
| 01/31/2001 | EP1071696A1 Programmed cell death and caspase-12 |
| 01/31/2001 | EP1071684A1 IMIDAZO 1,2-a]PYRIDINES AS PERIPHERAL BENZODIAZEPINE RECEPTOR BINDING AGENTS |
| 01/31/2001 | EP1071680A1 N,n-disubstituted amides that inhibit the binding of integrins to their receptors |
| 01/31/2001 | EP1071679A1 Novel heterocyclic compounds |
| 01/31/2001 | EP1071668A1 5-aminoindeno(1,2-c)pyrazol-4-ones as anti-cancer and anti-proliferative agents |
| 01/31/2001 | EP1071665A1 Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes |
| 01/31/2001 | EP1071658A2 Btk inhibitors and methods for their identification and use |
| 01/31/2001 | EP1071646A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds |
| 01/31/2001 | EP1071645A1 Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds |
| 01/31/2001 | EP1071485A2 Revascularization apparatus having coaxial channeling and injection means |
| 01/31/2001 | EP1071474A1 Substituted porphyrins |
| 01/31/2001 | EP1071459A1 Methods to provoke anti-cancer immune responses |
| 01/31/2001 | EP1071449A2 Antagonists of the inflammatory mediator oncostatin m (osm) |
| 01/31/2001 | EP1071448A1 Use of protease inhibitors for treating skin wounds |
| 01/31/2001 | EP1071447A1 Treatment for diabetes |
| 01/31/2001 | EP1071445A2 Therapeutic angiogenic factors and methods for their use |
| 01/31/2001 | EP1071439A1 Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis |
| 01/31/2001 | EP1071437A1 Streptococcus preparation |
| 01/31/2001 | EP1071434A1 Cnre binding factors and uses thereof |
| 01/31/2001 | EP1071433A2 Pharmaceutical composition |
| 01/31/2001 | EP1071431A1 Novel delivery of hydroxy carboxylic acids |
| 01/31/2001 | EP1071430A1 Treatment of iatrogenic and age-related hypertension with vitamin b6 derivatives and pharmaceutical compositions useful therein |
| 01/31/2001 | EP1071428A2 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 01/31/2001 | EP1071427A1 Intermittent claudication therapeutic drugs comprising pyrroloazepines |
| 01/31/2001 | EP1071426A2 Novel compounds and their use as positive ampa receptor modulators |
| 01/31/2001 | EP1071424A1 Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph |
| 01/31/2001 | EP1071419A1 Cannabinoids as antioxidants and neuroprotectants |
| 01/31/2001 | EP1071417A1 Use of cannabinoids as anti-inflammatory agents |
| 01/31/2001 | EP1071414A1 Compounds and methods for treating mitochondria-associated diseases |
| 01/31/2001 | EP1071411A1 Topical immunostimulation to induce langerhans cell migration |
| 01/31/2001 | EP1071377A1 Needleless administration of polynucleotide formulations |
| 01/31/2001 | EP1071333A1 Induction of immunity against tumor self-antigens |
| 01/31/2001 | EP1071329A1 Methods and compositions for treatment of aids-associated kaposi's sarcoma |
| 01/31/2001 | EP0920528A4 Synthetic protein folding catalysis |
| 01/31/2001 | EP0785774B1 Targeted delivery via biodegradable polymers |
| 01/31/2001 | CN1282372A Mammalian sytokine-like polypeptide-10 |
| 01/31/2001 | CN1282371A Ac (DNA encoding C6 beta-chemokine leukotactin-1 (Lkn-1) isolated from human |
| 01/31/2001 | CN1282338A A DNA molecule encoding mutant prepro-neuropeptide Y, a mutant signal peptide, and uses thereof |
| 01/31/2001 | CN1282334A Mitochondrially targeted antioxidants |
| 01/31/2001 | CN1282330A Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and their use to reduce TNF & alpha levels |
| 01/31/2001 | CN1282329A I (ortho)-anthranilamide derivatives as anti-coagulants |
| 01/31/2001 | CN1282322A 1,4-diazacycloheptane derivatives |
| 01/31/2001 | CN1282319A Aminobutanoic acid derivatives |
| 01/31/2001 | CN1282316A Substituted cyslopentane and cyclopentene compounds useful as neuraminidase inhibitors |
| 01/31/2001 | CN1282255A IFNAR2/I FN complex |